Transcranial Direct Current Stimulation (tDCS) in Treatment-Resistant Depression - Full Text View

Sponsored by:	Ludwig-Maximilians - University of Munich
Information provided by:	Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier:	NCT00667680

Purpose

tDCS applies a small amount of direct electric current (DC) to the brain by means of two electrodes: the one is an active electrode, localized on the effective site, and the other is a reference electrode, localized on some "silent" part of the body. Anodal transcranial direct current stimulation (tDCS) of the left dorsolateral prefrontal cortex (DLPFC) has been associated with working memory enhancement and improvement of mood. This study will investigate the possible antidepressant effects of tDCS in patients with therapy resistant major depressive episodes.

Condition	Intervention	Phase
Therapy Resistant Major Depression	Device: Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator	Phase II

MedlinePlus related topics: Depression Memory

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Transcranial Direct Current Stimulation (tDCS) in Treatment-Resistant Depression - Effect on Clinical and Neurophysiological Parameters

Further study details as provided by Ludwig-Maximilians - University of Munich:

Primary Outcome Measures:

Hamilton Psychiatric Rating Scale for Depression (HRSD-24) [ Time Frame: 6 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Beck depression Inventory (BDI) Clinical Global Impression (CGI) Mini-Mental-Status-Test (MMST) Verbal Learning and Memory Test (VLMT) Regensburger Word Fluency Test (RWT) [ Time Frame: 4 ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	20
Study Start Date:	March 2007
Estimated Study Completion Date:	November 2008
Estimated Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Active Comparator anodal tDCS	Device: Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
2: Sham Comparator Sham tDCS	Device: Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)

Detailed Description:

Transcranial direct current stimulation (tDCS) is a non-invasive method that shifts membrane potential towards hypo- or hyperpolarization and therefore leads to functional changes in a discrete area of the cerebral cortex.

Neurophysiological studies have shown that slow changes in cortical scalp potential reflect overall activity of cortical neuronal networks. These scalp potentials reflect shifts in membrane potentials of the cortical neurons. Over the past 7 years tDCS has evolved as an important tool to non-invasively manipulate specific neural circuits of the human brain.

The purpose of this study is an investigation of tDCS applied to 20 therapy-resistance major depressive patients. Our hypothesis is that tDCS may exert an antidepressant effect and/or enhances the medication effect. tDCS will be examined in the framework of a placebo-controlled clinical pilot-study investigating effectiveness, safety and influence on EEG parameters. Patients will receive anodal DC stimulation or sham stimulation (extra designed placebo-stimulator) in a double-blind design over 10 days for each condition. Outcomes will be evaluated using several clinical, psychiatric and neuropsychological rating scales.

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age 18-75 years
At least moderate major depressive episode (DSM IV criteria).
Stable total pre-treatment Hamilton Rating Scale for Depression score ≥18
Therapy-resistance during current depressive episode (according to ATHF).
The patient must be in the condition to understand the patient-information, as well as the necessary examinations. He/she must be able to give a written consent.
Stable antidepressant medication, that is retained during the study- duration, from at least three weeks before the begin of the study.

Exclusion Criteria:

Existence of a care/legal incapacity
Existing pregnancy
Severe psychiatric illness (with exception of affective disorder)
Acute suicidality
Drug-, medication- or alcohol dependence
Dementia according to DSM IV / ICD 10-criterions
Severe TBI in the anamnesis
Indications of structural damage of the basal ganglia or the brain stem
Severe neurological disorders (e.g. M. Parkinson, epilepsy, discus-prolapse, dementia, systemic neurological illnesses, normal pressure hydrocephalus, cerebrovascular diseases, elevated intracranial pressure, in the last 6 months, polyneuropathies).
Severe other medical conditions, like manifest arterial hypertonia, severe heart disease, pacemakers, respiratory failure, malignant illnesses all type, also in the history, active infectious diseases, skeletal disorders (like M. Paget, osteoporosis with spontaneous fractures, fresh fractures)
Other circumstances, that speaks against a participation of the patient pinion of MD at this study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00667680

Contacts

Contact: Frank Padberg, MD, PhD	49-89-5160-5879	padberg@med.uni-muenchen.de
Contact: Daniel Keeser, MSc	49-89-153-314	daniel.keeser@med.uni-muenchen.de

Locations

Germany
Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University Munich	Recruiting
Munich, Germany, 80336
Contact: Frank Padberg, MD, PhD, PD 49-89-5160-5879 padberg@med.uni-muenchen.de
Contact: Daniel Keeser, MSc 49-89-153-314 daniel.keeser@med.uni-muenchen.de

Sponsors and Collaborators

Ludwig-Maximilians - University of Munich

Investigators

Principal Investigator:

Frank Padberg, MD, PhD

Dept. of Psychiatry, Ludwig-Maximilians-University Munich

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Dept. of Psychiatry, Ludwig-Maximilians-University Munich ( Frank Padberg, MD, PhD )
Study ID Numbers:	01/2007
Study First Received:	April 24, 2008
Last Updated:	April 25, 2008
ClinicalTrials.gov Identifier:	NCT00667680 History of Changes
Health Authority:	Germany: Ethics Commission

Keywords provided by Ludwig-Maximilians - University of Munich:

tDCS, major depression

Study placed in the following topic categories:

Depression
Mental Disorders
Mood Disorders

Depressive Disorder, Major
Depressive Disorder
Behavioral Symptoms

Additional relevant MeSH terms:

Depression
Mental Disorders
Mood Disorders

Depressive Disorder, Major
Depressive Disorder
Behavioral Symptoms

ClinicalTrials.gov processed this record on May 07, 2009